📣 Send us your press release
Site updates every 15 minutes
Health

AcuCort files FDA application for Zeqmelit in the United States

Swedish pharmaceutical company AcuCort has submitted a New Drug Application to the U.S. Food and Drug Administration for its oral dexamethasone film, Zeqmelit.

16 November 2026

AcuCort confirmed the filing of its New Drug Application (NDA) for Zeqmelit with the U.S. Food and Drug Administration (FDA) today. The submission utilizes the 505(b)(2) regulatory pathway, a mechanism that allows for approval based on existing clinical data and safety profiles, potentially accelerating the review process for previously approved active ingredients.

This application represents a shift for the Stockholm-based company as it seeks to expand its footprint from European markets into the United States. Zeqmelit is an oral film formulation of the corticosteroid dexamethasone, designed to provide a rapid administration method for patients suffering from acute allergic reactions.

The regulatory filing initiates the formal review process required for U.S. market authorization. CEO Jonas Jönmark scheduled an investor presentation for this afternoon to discuss the company's strategic roadmap following the submission.

Original source: news.cision.com